LCRF Research Grants on Oncogenic Drivers in Lung Cancer

To better understand oncogene-driven lung cancers, LCRF has launched a new funding mechanism to support research projects with a focus on characterizing, identifying, treating or overcoming/preventing resistance to therapies in tumors harboring alterations in oncogenic drivers in NSCLC cells, tissues, mouse models, or patients. The foundation encourages applications on a wide variety of topics related to EGFR, MET or KRAS-driven lung cancer, including, but not limited to the following:

• Biology and mechanisms of tumor progression
• Mechanisms of resistance to targeted therapies
• Novel treatment approaches, combinations, and new therapies
• Studies on the immune landscape, tumor microenvironment, and immunotherapies

Funding: $150,000
Duration: 2 years

Research Authority deadline: 24.4.22

LOI (required) due date: 30.4.22

Full proposal due date: 29.8.22